There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

President-elect Donald Trump, a Biden administration proposal would require Medicare and Medicaid to cover weight-loss drugs ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the dual ...

The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such as ...